Latest Content

The phase 3 EMERALD-3 trial shows Imfinzi and Imjudo plus Lenvima and embolization improved progression-free survival in unresectable liver cancer.

The FDA fully approved Tecartus for adult patients with relapsed or refractory mantle cell lymphoma based on high response rates in the ZUMA-2 trial.

A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care without invasive surgery.

A study found blood-based genomic testing can be completed in 27 hours, giving patients with cancer faster treatment decisions.

Eleven years with Stage 4 breast cancer, all on the first line of treatment. It isn’t chronic, but what is it?

Multiple myeloma survivor JP Kealy and wife Annamarie share how to avoid cancer burnout and why this journey is a marathon, not a sprint.

A phase 3 trial finds anbenitamab and docetaxel improve response rates in patients with HER2-positive breast cancer and offer a safer delivery.

A couple opens up about navigating cancer care, advocating for themselves and balancing caregiver responsibilities with self-care.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

The 49th Annual Miami Breast Cancer Conference recently hosted a cornerstone event for the advocacy community: the CURE Educated Patient® Breast Cancer Summit.

Dr. Susan MacDonald, a urologist who has been diagnosed with stage 4 breast cancer, launches a new vlog series for CURE, “Demystifying the Darkness.”

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

Author and survivor Parul Somani shares how patients with breast cancer can find peace of mind when clinical certainty is missing.